Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$23.52 +0.2%	$19.73	$15.47 ▼ $36.37	$804.69M	1.26	195,635 shs	219,200 shs
CTMX CytomX Therapeutics	$2.64 +10.0%	$1.33	$0.40 ▼ $2.82	$212.84M	1.11	2.16 million shs	3.41 million shs
DAWN Day One Biopharmaceuticals	$7.19 +3.5%	$6.94	$6.08 ▼ $16.76	$728.79M	-1.3	1.12 million shs	1.45 million shs
TRVI Trevi Therapeutics	$7.06 +4.7%	$6.26	$2.30 ▼ $7.48	$705.25M	0.59	1.32 million shs	2.49 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	+0.21%	+10.94%	+19.00%	+7.54%	+25.98%
CTMX CytomX Therapeutics	+10.00%	+4.76%	+171.33%	+297.05%	+58.08%
DAWN Day One Biopharmaceuticals	+3.45%	+12.52%	+14.13%	-17.07%	-44.95%
TRVI Trevi Therapeutics	+4.75%	+8.62%	+6.01%	+64.19%	+164.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.3794 of 5 stars	3.6	0.0	0.0	2.8	0.8	0.0
CTMX CytomX Therapeutics	4.5609 of 5 stars	3.5	2.0	4.7	3.8	2.5	1.3
DAWN Day One Biopharmaceuticals	1.701 of 5 stars	3.6	0.0	0.0	2.6	2.5	0.0
TRVI Trevi Therapeutics	3.6114 of 5 stars	4.7	3.0	0.0	2.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	67.03% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	102.02% Upside
DAWN Day One Biopharmaceuticals	3.13	Buy	$30.57	325.19% Upside
TRVI Trevi Therapeutics	3.30	Buy	$18.63	163.81% Upside

Current Analyst Ratings Breakdown

Latest CTMX, AVBP, DAWN, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/2/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00
5/28/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/20/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/7/2025	DAWN Day One Biopharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$25.00
5/7/2025	DAWN Day One Biopharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $27.00

(Data available from 6/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	($4.79) per share	N/A
CTMX CytomX Therapeutics	$147.56M	1.44	N/A	N/A	($0.71) per share	-3.72
DAWN Day One Biopharmaceuticals	$161.92M	4.50	N/A	N/A	$3.98 per share	1.81
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$69.33M	-$3.77	N/A	N/A	N/A	N/A	-43.89%	-29.67%	8/13/2025 (Estimated)
CTMX CytomX Therapeutics	-$570K	$0.48	15.53	N/A	N/A	10.96%	-41.47%	8.11%	8/14/2025 (Estimated)
DAWN Day One Biopharmaceuticals	-$188.92M	-$0.71	N/A	N/A	N/A	N/A	-22.40%	-19.79%	7/8/2025 (Estimated)
TRVI Trevi Therapeutics	-$29.07M	-$0.45	N/A	N/A	N/A	N/A	-63.31%	-57.06%	8/14/2025 (Estimated)

Latest CTMX, AVBP, DAWN, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/6/2025	Q1 2025	DAWN Day One Biopharmaceuticals	-$0.46	-$0.35	+$0.11	-$0.35	$30.28 million	$30.76 million
5/6/2025	Q1 2025	TRVI Trevi Therapeutics	-$0.13	-$0.09	+$0.04	-$0.09	N/A	N/A
3/18/2025	Q4 2024	TRVI Trevi Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	19.28	19.28
CTMX CytomX Therapeutics	N/A	1.04	1.04
DAWN Day One Biopharmaceuticals	N/A	14.62	14.55
TRVI Trevi Therapeutics	N/A	7.38	7.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
CTMX CytomX Therapeutics	67.77%
DAWN Day One Biopharmaceuticals	87.95%
TRVI Trevi Therapeutics	95.76%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
CTMX CytomX Therapeutics	7.00%
DAWN Day One Biopharmaceuticals	6.20%
TRVI Trevi Therapeutics	18.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	N/A	N/A
CTMX CytomX Therapeutics	170	80.62 million	72.78 million	Optionable
DAWN Day One Biopharmaceuticals	60	101.36 million	92.38 million	Optionable
TRVI Trevi Therapeutics	20	99.89 million	58.13 million	Optionable

CTMX, AVBP, DAWN, and TRVI Headlines

Recent News About These Companies

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC

June 7 at 3:21 AM | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen

June 7 at 12:20 AM | marketbeat.com

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

June 5 at 4:30 PM | prnewswire.com

Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI)

June 5 at 3:14 AM | marketbeat.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Time to Buy?

June 4 at 10:52 AM | marketbeat.com

D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)

June 4 at 2:14 AM | americanbankingnews.com

Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $18.63

June 4 at 1:37 AM | americanbankingnews.com

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

June 3, 2025 | prnewswire.com

Trevi Therapeutics (NASDAQ:TRVI) Stock Price Down 7.1% - Here's Why

June 3, 2025 | marketbeat.com

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

June 2, 2025 | prnewswire.com

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

June 2, 2025 | benzinga.com

Trevi Therapeutics (NASDAQ:TRVI) Reaches New 12-Month High - What's Next?

June 2, 2025 | marketbeat.com

Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at D. Boral Capital

June 2, 2025 | marketbeat.com

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 2, 2025 | prnewswire.com

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

June 1, 2025 | prnewswire.com

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts

June 1, 2025 | marketbeat.com

What is HC Wainwright's Forecast for TRVI Q2 Earnings?

June 1, 2025 | americanbankingnews.com

Research Analysts Issue Forecasts for TRVI Q2 Earnings

May 31, 2025 | marketbeat.com

HC Wainwright Initiates Coverage on Trevi Therapeutics (NASDAQ:TRVI)

May 30, 2025 | americanbankingnews.com

H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating

May 29, 2025 | msn.com

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up - Still a Buy?

May 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTMX, AVBP, DAWN, and TRVI Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$23.52 +0.05 (+0.21%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$22.00 -1.52 (-6.46%)

As of 06/6/2025 05:42 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

CytomX Therapeutics NASDAQ:CTMX

$2.64 +0.24 (+10.00%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$2.66 +0.01 (+0.57%)

As of 06/6/2025 07:23 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Day One Biopharmaceuticals NASDAQ:DAWN

$7.19 +0.24 (+3.45%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$7.07 -0.12 (-1.67%)

As of 06/6/2025 06:33 PM Eastern

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Trevi Therapeutics NASDAQ:TRVI

$7.06 +0.32 (+4.75%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$7.06 0.00 (-0.07%)

As of 06/6/2025 07:45 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time